Table 1 Clinical and laboratory characteristics of the study cohort
Variable | Frequency | Percent | Variable | Frequency | Percent | ||
|---|---|---|---|---|---|---|---|
Age: median (range) | 7 (1–18) | TLC: median (range) | 187.6 (2–967) | ||||
HB: median (range) | 7.7 (4–14.5) | Platelets: median (range) | 48 (8–693) | ||||
PB blast: median (range) | 82 (0–99) | BM blast: median (range) | 89 (0–99) | ||||
MCN: median (range) | 46 (range: 41–91) | MCN | Normal | 46 | 73.0 | ||
Sex | Male | 44 | 69.8 | Hypodiploidy | 6 | 9.5 | |
Female | 19 | 30.2 | Hyperdiploidy | 11 | 17.5 | ||
Initial CNS | CNSI | 48 | 76.2 | IPT diagnosis | T intermediate | 17 | 27.0 |
T early | 16 | 25.4 | |||||
TLP | 13 | 20.6 | T late | 23 | 36.5 | ||
CNSIII | 2 | 3.2 | ETP | 7 | 11.1 | ||
BM cellularity | Hypercellular | 51 | 81 | CD1 | Negative | 12 | 19.0 |
Normocellular | 12 | 19 | Positive | 51 | 81.0 | ||
CD117 | Negative | 50 | 79.4 | CD7 | Negative | 26 | 41.3 |
Positive | 13 | 20.6 | Positive | 37 | 58.7 | ||
CD34 | Negative | 53 | 84.1 | CD3 surface | Negative | 53 | 84.1 |
Positive | 10 | 15.9 | Positive | 10 | 15.9 | ||
CD2 | Negative | 33 | 52.4 | CD5 | Negative | 44 | 69.8 |
Positive | 30 | 47.6 | Positive | 19 | 30.2 | ||
HLA-DR | Negative | 35 | 55.6 | TDT | Negative | 8 | 12.7 |
MHCII | 28 | 44.4 | Positive | 55 | 87.3 | ||
Complex (presence of 3 or more cytogenetics abnormalities) | Negative | 53 | 84.1 | Cytogenetics | Normal | 20 | 31.7 |
Positive | 10 | 15.9 | Abnormal | 43 | 68.3 | ||
MRD15a | < 0.01 | 10 | 21.7 | MRD42 | < 0.01 | 15 | 35.7 |
≥ 0.01 | 36 | 78.3 | ≥ 0.01 | 27 | 64.3 | ||
Induction outcome | CR | 52 | 82.5 | Relapse | Negative | 55 | 87.3 |
Induction death | 11 | 17.5 | Positive | 8 | 12.7 | ||
Early death | Negative | 52 | 82.5 | Death | Negative | 36 | 57.1 |
Positive | 11 | 17.5 | Positive | 27 | 42.9 | ||